Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript from the Q1FY26 earnings call. The company mentions having a healthy balance sheet with a cash surplus of Rs. 1,518 crores and a positive free cash flow of Rs. 935 crores. Discussion around capital expenditure (CAPEX) is ongoing, particularly for Jammu plant expansion and Baddi plant ramp-up, but this appears to be funded through existing cash and cash flows. The company is open to inorganic growth opportunities and may deploy cash for acquisitions, specifically targeting do

Any current/future capex/capital investment/strategic investment?

Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027. Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility. Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios. Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly. The company is open to inorgani

Future growth expectations in sales/revenue/volumes?

CDMO Business: - Expected mid-single-digit topline growth in FY26 due to continued soft API prices. - Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years. - Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports. Domestic Branded Formulations: - Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off. - Anticipated better performance in subsequent quarters, maintaining overall yearly guidance. International Branded Formulati

Future growth expectations in earnings/operating earnings/profits/EPS?

**CDMO Business**: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%. **Exports & European Business**: Aim to scale formulation exports from current $15 million to $100 million over the next five years, including a Rs. 300 crore contract starting FY28. **Domestic Branded Formulation**: Growth expected to track or slightly outpace Indian Pharmaceutical Market (IPM) growth after a subdued Q1; full-year EBITDA margins steady around 18%. **Trade Generics & API Segments**: Trade generics being rationalized to profit

Current/ Expected Orderbook/ Pending Orders?

Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets. They have other ongoing contracts of smaller values in progress. Current export business run rate stands at Rs. 150 crores. Over a five-year horizon, the company targets around $100 million in exports from the CDMO and international branded formulation segments combined. The company is also working on expanding its European dossier approvals, including recently approved Rivaroxaban and upcoming dossiers like Dapagliflozin. There is no explicit mention of the total outstan

IN US

Sale is live|00:00:00left today

Akums Drugs & Pharmaceuticals LtdQ2 FY25Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹609P/E: 26.6Market Cap: ₹8.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→CDMO Business:
→ - Expected mid-single-digit topline growth in FY26 due to continued soft API prices.
→ - Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years.
→ - Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports.
→Domestic Branded Formulations:
→ - Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off.
→ - Anticipated better performance in subsequent quarters, maintaining overall yearly guidance.
→International Branded Formulations:
→ - High-teen growth expected for the full year despite weaker current quarter.
→API Business:
→ - Continued focus on global expansion (Europe, Africa, LATAM) and improved API pricing.
→ - Single-digit growth expected amidst pricing pressure domestically.
→Trade Generics:
→ - Gradual rationalization expected; potential profitable units retained but no significant growth anticipated.

Margin guidance

Category 3

→**CDMO Business**: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.
→**Exports & European Business**: Aim to scale formulation exports from current $15 million to $100 million over the next five years, including a Rs. 300 crore contract starting FY28.
→**Domestic Branded Formulation**: Growth expected to track or slightly outpace Indian Pharmaceutical Market (IPM) growth after a subdued Q1; full-year EBITDA margins steady around 18%.
→**Trade Generics & API Segments**: Trade generics being rationalized to profitable units; API business loss reducing with global expansion focus, aiming for positive EBITDA by FY26.
→**Overall**: Healthy EBITDA growth in Q1FY26 (+19% YoY), strong free cash flow, and prudent capital allocation support sustainable and profitable growth ahead.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript from the Q1FY26 earnings call.
→The company mentions having a healthy balance sheet with a cash surplus of Rs. 1,518 crores and a positive free cash flow of Rs. 935 crores.
→Discussion around capital expenditure (CAPEX) is ongoing, particularly for Jammu plant expansion and Baddi plant ramp-up, but this appears to be funded through existing cash and cash flows.
→The company is open to inorganic growth opportunities and may deploy cash for acquisitions, specifically targeting dosage form capabilities or access to new markets.
→No new debt or equity fundraising is indicated as an immediate plan; focus remains on utilizing existing cash reserves for growth and expansion.

Order book

→Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets.
→They have other ongoing contracts of smaller values in progress.
→Current export business run rate stands at Rs. 150 crores.
→Over a five-year horizon, the company targets around $100 million in exports from the CDMO and international branded formulation segments combined.
→The company is also working on expanding its European dossier approvals, including recently approved Rivaroxaban and upcoming dossiers like Dapagliflozin.
→There is no explicit mention of the total outstanding order book value, but the pipeline appears strong with new product filings and contract onboarding, targeting scalable growth over 3-5 years.

Capex plans

Yes

→Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
→Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility.
→Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios.
→Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly.
→The company is open to inorganic opportunities, supported by a healthy balance sheet and cash surplus of Rs. 1,518 crores.
→Overseas expansion through European market plays including dossier filings and registration via Akums Healthcare UK, aiming to build a larger portfolio with exclusive marketing authorizations over time.

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Akums Drugs & Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio